Insider Selling: Neuronetics (NASDAQ:STIM) Major Shareholder Sells $599,421.56 in Stock

Neuronetics, Inc. (NASDAQ:STIM – Get Free Report) major shareholder Jorey Chernett sold 250,804 shares of the stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $2.39, for a total value of $599,421.56. Following the transaction, the insider owned 10,370,184 shares in the company, valued at $24,784,739.76. This represents a 2.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Jorey Chernett also recently made the following trade(s):

  • On Friday, November 13th, Jorey Chernett sold 2,187,051 shares of Neuronetics stock. The shares were sold at an average price of $1.15, for a total value of $2,515,108.65.
  • On Thursday, November 12th, Jorey Chernett sold 706,840 shares of Neuronetics stock. The shares were sold at an average price of $1.43, for a total value of $1,010,781.20.
  • On Wednesday, November 11th, Jorey Chernett sold 86,757 shares of Neuronetics stock. The shares were sold at an average price of $1.61, for a total value of $139,678.77.
  • On Monday, November 9th, Jorey Chernett sold 103,959 shares of Neuronetics stock. The stock was sold at an average price of $2.06, for a total value of $214,155.54.
  • On Monday, November 9th, Jorey Chernett bought 40,000 shares of Neuronetics stock. The shares were acquired at an average cost of $1.99 per share, with a total value of $79,600.00.
  • On Friday, October 30th, Jorey Chernett bought 18,000 shares of Neuronetics stock. The shares were acquired at an average price of $2.27 per share, for a total transaction of $40,860.00.

Neuronetics Stock Performance

Shares of NASDAQ:STIM opened at $1.39 on Monday. The business’s 50 day moving average price is $2.35 and its 200-day moving average price is $1.87. Neuronetics, Inc. has a 1 year low of $0.80 and a 1 year high of $3.44. The firm has a market capitalization of $108.04 million, a price-to-earnings ratio of -4.21 and a beta of 1.36. The company has a debt-to-equity ratio of 2.76, a current ratio of 2.01 and a quick ratio of 1.82.

Neuronetics (NASDAQ:STIM – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.07. The company had revenue of $41.96 million during the quarter, compared to analyst estimates of $40.42 million. Neuronetics had a negative net margin of 14.45% and a negative return on equity of 102.23%. On average, equities research analysts forecast that Neuronetics, Inc. will post -0.30 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on STIM shares. Citigroup reiterated a “market outperform” rating on shares of Neuronetics in a research report on Tuesday, July 21st. B. Riley Financial upped their price target on shares of Neuronetics from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. BTIG Research reaffirmed a “buy” rating and issued a $6.00 price target on shares of Neuronetics in a research note on Thursday, September 17th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Neuronetics in a report on Monday, September 14th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $5.00.

Check Out Our Latest Report on Neuronetics

Institutional Trading of Neuronetics

Several large investors have recently bought and sold shares of the business. Jump Financial LLC acquired a new stake in Neuronetics in the 3rd quarter valued at about $69,000. Marshall Wace LLP lifted its stake in Neuronetics by 219.5% in the 3rd quarter. Marshall Wace LLP now owns 1,551,840 shares of the company’s stock worth $3,631,000 after purchasing an additional 1,066,148 shares in the last quarter. Empowered Funds LLC purchased a new position in Neuronetics in the 3rd quarter worth approximately $211,000. HighTower Advisors LLC lifted its stake in Neuronetics by 95.4% in the 3rd quarter. HighTower Advisors LLC now owns 1,101,502 shares of the company’s stock worth $2,578,000 after purchasing an additional 537,761 shares in the last quarter. Finally, Jefferies Financial Group Inc. acquired a new position in shares of Neuronetics during the 3rd quarter worth approximately $176,000. Hedge funds and other institutional investors own 53.59% of the company’s stock.

More Neuronetics News

These are some of the STIM news items that stood out recently:

  • Positive Sentiment: Third-quarter revenue was $41.96 million, above the $40.43 million analyst estimate, while its $0.02-per-share loss was narrower than the expected $0.09 loss. The results may support sentiment about improving performance. Article: Neuronetics stock: Q3 revenue rises as loss narrows
  • Negative Sentiment: Major shareholder Jorey Chernett disclosed several sales from November 6–13, totaling about 3.34 million shares, partly offset by a 40,000-share purchase. After the latest sale, Chernett held about 7.33 million shares. The scale of the selling may raise concerns about near-term supply and investor confidence. SEC filing on Chernett’s transactions

About Neuronetics

(Get Free Report)

Neuronetics, Inc. is a medical technology company that develops and commercializes noninvasive treatments for certain mental health conditions. Its flagship product is the NeuroStar Advanced Therapy System, which uses transcranial magnetic stimulation to deliver targeted magnetic pulses to areas of the brain. NeuroStar is FDA-cleared for treating major depressive disorder in adults who have not achieved satisfactory improvement with antidepressant medication. The company also provides treatment-related services and support for clinicians and patients.

Featured Articles

Insider Buying and Selling by Quarter for Neuronetics (NASDAQ:STIM)

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.